Financial news in brief: Avecho CBD trial latest; Argent’s milestone delivery; Neurotech reassures ASX by Steve Jones April 29, 2026June 8, 2026 Avecho Biotechnology dosed 244 patients in its phase III insomnia trial, 16% above target, in a […]
News in brief: 150 applications for council CEO role; Rua sends NZ genetics to Canada; Argent completes pet business deal by Steve Jones April 15, 2026April 15, 2026
Financial news in brief: Avecho; InhaleRx; Neurotech; Peak; Zelira; Argent by Adam Sheldon February 2, 2026June 8, 2026
Argent inks binding agreement to buy AusCann’s CannPal stake by Adam Sheldon January 15, 2026January 15, 2026
Argent BioPharma secures A$11m facility to complete AusCann acquisition by Adam Sheldon November 17, 2025February 21, 2026
Argent BioPharma inks deal to acquire AusCann assets and IP by Martin Lane August 19, 2025August 21, 2025
News in brief: Althea completes medical cannabis asset sales; Argent begins clinical supply in Slovenia; ECS backs UWA trial for sleep apnoea by Adam Sheldon July 8, 2025July 9, 2025
Argent Biopharma and Auscann sign deal to ‘enhance drug development’ by Steve Jones April 23, 2025April 23, 2025
News in brief: TGA ponders rule change; no repeal of German law; Argent signs Malta deal; new role for Kylie O’Brien by Steve Jones April 10, 2025April 10, 2025
News in brief: Rua’s German stock shortage; Zelira’s finance deal; cultivator nets $1.4m; Neurotech exec steps down; ‘major milestone’ for Argent; Cann Group pharmacy deal by Steve Jones and Martin Lane April 3, 2025April 3, 2025
